NOTICIAS DIARIAS

Lower Dementia Risk In Black Patients With Type 2 Diabetes Mellitus

Lower Dementia Risk In Black Patients With Type 2 Diabetes Mellitus
Lower Dementia Risk In Black Patients With Type 2 Diabetes Mellitus
Pathology & Microbiology

As the type 2 diabetes mellitus is almost twice as prevalent among African Americans as non-Hispanic whites. Metformin use is associating with a substantially lower risk for dementia; among younger African-American patients with diabetes comparing with sulfonylurea initiation. Diabetes is a risk factor for dementia.

But according to the research studies; medical record data to identify 73,761 African-American and white patients; who were free of dementia and diabetes medications at baseline but subsequently initiated metformin or sulfonylurea monotherapy. The age-adjusting prevalence of T2DM is 13.4% in African Americans and 7.3% in whites. African American patients on average have worse glycemic control and more diabetes-related complications than white patients.

Diabetes mellitus, commonly known as diabetes, is a metabolic disease that causes high blood sugar. The hormone insulin moving sugar from the blood into your cells to be stored or using for energy. With diabetes, your body either does not make enough insulin or can not effectively use the insulin it does make.

Type 2 diabetes mellitus

When controlling for other variables, the researchers finding that metformin use was associating with a significantly lower risk for dementia comparing with sulfonylurea use in African-American patients (hazard ratio [HR], 0.73; 95 percent confidence interval [CI], 0.6 to 0.89) but not among white patients (HR, 0.96; 95 percent CI, 0.9 to 1.03). This disparity is greater in patients aging 55 to 65 years comparing with older patients.

The association was strongest among African-American patients aging 50 to 64 years (HR, 0.6; 95 percent CI, 0.45 to 0.81). Metformin was significantly associating with a lower risk for dementia in both races for older patients. There was no association between metformin use and dementia in patients aged ≥75 years. Emerging evidence from observational studies with robust control for confounding suggests that a first-line diabetes medication, metformin, compared with sulfonylureas, is associated with an 8% to 10% decrease in dementia risk.

Psychosocial determinants of health

Finally, psychosocial determinants of health, such as social support, are not available in medical record data but could influence the association between metformin use and dementia. This unable to draw definitive conclusions regarding cause and effect; and clinical trials are necessary to confirm the hypothesis that metformin use is associating with a reducing risk of dementia; and confirm that the magnitude of the association is greater in African American comparingwith white patients with T2DM.

However, there are no existing medications to prevent dementia. The 29% decreased risk of dementia associated with metformin use in African American patients aged 65 to 74 years and the 40% decreased risk in those aged 50 to 64 years suggest that someday this inexpensive, widely available treatment could be broadly prescribed to substantially reduce the risk of dementia in younger African American patients with T2DM.